Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P

Clinical Cancer Research

Volumn 12, Issue 12, 2006, Pages 3843-3850

  Kneifel, Stefan ^a   Cordier, Dominik ^b   Good, Stephan ^a   Ionescu, Mihai C S ^a   Ghaffari, Anthony ^b   Hofer, Silvia ^b   Kretzschmar, Martin ^a   Tolnay, Markus ^a   Apostolidis, Christos ^c   Waser, Beatrice ^d   Arnold, Marlene ^d   Mueller Brand, Jan ^a   Maecke, Helmut R ^a   Reubi, Jean Claude ^d   Merlo, Adrian ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Neurologische Universitatsklinik Basel   (Switzerland)

^c JOINT RESEARCH CENTRE   (Italy)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1 GLUTARIC ACID 4,7,10 TRIACETIC ACID SUBSTANCE P; ARGININE; BISMUTH 213; CHELATING AGENT; NEUROKININ 1 RECEPTOR; PEPTIDE; RADIOPHARMACEUTICAL AGENT; STEROID; TEMOZOLOMIDE; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOTOMY; CYTOLOGY; DIFFUSION; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; EDEMA; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; INCIDENCE; INTRACRANIAL PRESSURE; ISOTOPE LABELING; MALE; MOLECULAR WEIGHT; NERVOUS SYSTEM FUNCTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION NECROSIS; TUMOR BIOPSY; TUMOR CELL LINE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; GLIOMA; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RADIOPHARMACEUTICALS; RESTRICTION MAPPING; SUBSTANCE P; YTTRIUM RADIOISOTOPES;

EID: 33745697736     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2820     Document Type: Article

References (46)

1. Kleihues P, Burger P, Scheithauer B. Histological typing of tumours of the central nervous system. WHO, international histological classification of tumours. 2nd ed. Berlin (Germany): Springer; 1993.
2. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33.
3. Merlo A. Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev 2003;26:145-58.
4. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992;76:428-34.
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
6. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
7. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
8. Oertel J, von Buttlar E, Schroeder HW, Gaab MR. Prognosis of gliomas in the 1970s and today. Neurosurg Focus 2005;18:e12
9. Burger PC. What is an oligodendroglioma? Brain Pathol 2002;12:257-9.
10. Keene DL, Hsu E, Ventureyra E. Brain tumors in childhood and adolescence. Pediatr Neurol 1999;20:198-203.
11. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.
12. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8.
13. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004;101:1004-11.
14. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157-65.
15. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18:3862-72.
16. 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. Int J Cancer 1997;71:810-6.
17. 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 1995;55:5952-6s.
18. Maecke HR. Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop 2005:43-72.
19. Otte A, Mueller-Brand J, Delias S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-8.
20. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-5.
21. 3-octreotide radiopeptide brachytherapy. Cancer 2005;103:869-73.
22. 3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 1999;5:1025-33.
23. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61:786-92.
24. Beaujouan JC, Torrens Y, Saffroy M, Kernel ML, Glowinski J. A 25 year adventure in the field of tachykinins. Peptides 2004;25:339-57.
25. Mitrovic B, Martin FC, Charles AC, et al. Neurotransmitters and cytokines in CNS pathology. Prog Brain Res 1994;103:319-30.
26. Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A 1997;94:12479-84.
27. ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
28. Maier D, Jones G, Li X, et al. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 1999;59:5479-82.
29. Schmassmann A, Waser B, Flogerzi B, Reubi JC. Expression of functional neurokinin-1 receptors in regenerative glands during gastric wound healing in rodents. Gastroenterology 2004;126:784-95.
30. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
31. Atherton E, Sheppard R. Fluorenylmethoxycarbonyl-polyamide solid phase peptide synthesis. General principles and development. Oxford: Information Press Oxford; 1989.
32. Eisenwiener KP, Powell P, Maecke HR. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg Med Chem Lett 2000;10:2133-5.
33. 225Ac in radioimmu-notherapy. Nuclear News 2001;44:29-33.
34. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
35. 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 2002;29:486-93.
36. Ruser G, Ritter W, Maecke HR. Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111. Bioconjug Chem 1990;1:345-9.
37. Sangha H, Lipson D, Foley N, et al. A comparison of the Barthel index and the functional independence measure as outcome measures in stroke rehabilitation: patterns of disability scale usage in clinical trials. Int J Rehabil Res 2005;28:135-9.
38. Cervera P, Videau C, Viollet C, et al. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol 2002;14:458-71.
39. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 1987;47:5758-64.
40. 177Lu. Nuklearmedizin 2004;43:A11.
41. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847-51.
42. Carson BS, Sr., Wu Q, Tyler B, et al. New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery. J Neurooncol 2002;60:151-8.
43. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-97
44. Parney IF, Kunwar S, McDermott M, et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005;102:267-75.
45. Wowra B, Schmitt HP, Sturm V. Incidence of late radiation necrosis with transient mass effect after interstitial low dose rate radiotherapy for cerebral gliomas. Acta Neurochir (Wien) 1989;99:104-8.
46. Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SW. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989;134:337-44.